Novo Nordisk (NVO) stock gained 1.85% to close at $45.71 on Tuesday, outperforming the broader market as investors focused on expanding access to its Wegovy obesity treatment through a new Medicare program. The move came even as pricing pressure remains a central concern for the Danish drugmaker.
The shares advanced while the S&P 500 declined 0.69%, giving Novo Nordisk a notable relative performance advantage during the session. However, the company’s Copenhagen-listed B shares moved in the opposite direction on Wednesday, trading around DKK 293.80 by 09:02 CEST, down 0.86%.
At the center of the latest investor debate is Medicare’s GLP-1 Bridge program, which began July 1 and is scheduled to run through the end of 2027. The initiative allows eligible Medicare Part D beneficiaries to obtain approved weight-loss medicines for a $50 monthly copay.
The $50 monthly payment is significantly lower than what many patients could otherwise face when paying out of pocket, potentially making Wegovy more accessible to a broader group of eligible Americans. The program covers both Wegovy tablets and injections, giving Novo Nordisk exposure across its expanding obesity-treatment portfolio.
According to the information provided by the Centers for Medicare & Medicaid Services, the manufacturer net price under the program is listed at $245 per monthly supply. That creates a complicated trade-off for investors: Novo could benefit from higher volumes, but lower realized prices may reduce the financial benefit of each additional patient.
Company data indicates that U.S. demand for Wegovy has been accelerating. By July 17, weekly prescriptions across the Wegovy franchise reached approximately 575,000, with the newly introduced pill accounting for more than 265,000 prescriptions.
That means the pill represented roughly 46% of total weekly Wegovy prescriptions at the time. Novo also reported that cumulative prescriptions for the oral version had passed five million after 30 weeks.
The figures highlight the potential importance of the tablet as Novo Nordisk competes in the increasingly crowded GLP-1 market. The pill gives the company another way to reach consumers who may prefer an oral treatment over an injectable option.
Novo’s second-quarter results also showed underlying growth. Adjusted sales increased 7% at constant exchange rates, while adjusted operating profit rose 11%. However, higher volumes were accompanied by lower realized prices, reinforcing the concern that prescription growth alone may not fully translate into stronger revenue.
Novo Nordisk is also facing increasingly intense competition from Eli Lilly (LLY), which gained 3.60% in Tuesday’s session and outperformed Novo by 1.75 percentage points.
Lilly’s Mounjaro and Zepbound franchises generated nearly $15 billion combined during the second quarter, underscoring the scale of the competitive threat. Medicare’s GLP-1 Bridge includes qualifying treatments from both companies, meaning Novo cannot assume that greater government-supported access will automatically translate into market-share gains.
The growing availability of oral and injectable treatments makes differentiation increasingly important. Novo’s Wegovy pill could become a significant competitive advantage if patients show a strong preference for tablets, but pricing and reimbursement remain critical factors.
Investors therefore face a delicate balance. Greater access could stimulate demand, but government-influenced pricing and competition could restrict the financial upside from that demand.
The post Novo Nordisk (NVO) Stock; Gains as $50 Medicare Wegovy Access Challenges Pricing appeared first on CoinCentral.
